KITE PHARMA

Recognize the urgency early in your patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) or follicular lymphoma (FL) who may be at high risk for poor outcomes. Choices made in early lines of treatment can provide important clinical information for later lines... NHL represents a varied spectrum of cancers of the immune system 1 and is among the most common types of cancers in the United States. 2 Between 2010 and 2016, the 5-year relative survival for NHL in the US was 72.7%. 2 DLBCL is the most common type of NHL in the United States, accounting for 89,099 cases (21.2%) from 2008 to 2017. 3 Follicular lymphoma is another common type of NHL, which accounted for 43,697 (10.4%) of NHL cases in the United States between 2008 and 2017. 3

Also known as: Is Danger Lurking, Kite Pharma, Inc.